N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)-(3-fluoro- phenyl)-amine by human UDP-glucuronosyltransferases

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 748-755

  Yan, Z ^a   Caldwell, G W ^a   Gauthier, D ^a   Leo, G C ^a   Mei, J ^a   Ho, C Y ^a   Jones, W J ^a   Masucci, J A ^a   Tuman, R W ^a   Galemmo Jr , R A ^a   Johnson, D L ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 N PYRAZOLE GLUCURONIDE; 2 N PYRAZOLE GLUCURONIDE; 6,7 (DIMETHOXY 2,4 DIHYDROINDENO[1,2 C]PYRAZOL 3 YL) (3 FLUOROPHENYL)AMINE; BETA GLUCURONIDASE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; ISOENZYME; JNJ 10198409; N AMINE GLUCURONIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG SOLUBILITY; ENZYME ACTIVATION; FEMALE; GLUCURONIDATION; HUMAN; HUMAN TISSUE; KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MICHAELIS CONSTANT; MONKEY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, COMPLEMENTARY; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLORHINI; HUMANS; INDANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES, LIVER; OXIDATION-REDUCTION; PROPOFOL; PYRAZOLES; RATS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

ANIMALIA;

EID: 33645816779     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009274     Document Type: Article

References (35)

1. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, et al. (2004) Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 498:9-18.
2. Chiu SH and Huskey SW (1998) Species differences in N-glucuronidation. Drug Metab Dispos 26:838-847.
3. D'Andrea RM, Mei MJ, Tuman WR, Galemmo RA, and Johnson DL (2005) Validation of in vivo pharmacodynamic action of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther 4:1198-1204.
4. Dulik DM and Fenselau C (1987) Species-dependent glucuronidation of drugs by immobilized rabbit, rhesus monkey and human UDP-glucuronyl transferases. Drug Metab Dispos 15:473-477.
5. Ekins S, Ring BJ, Binkley SN, Hall SD, and Wrighton SA (1998) Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 36:642-651.
6. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
7. Girard H, Court MH, Bernard O, Fortier L-C, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, and Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515.
8. Green MD and Tephly TR (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860-867.
9. Ho CY, Ludovici DW, Maharoof USM, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen H-K, Leo G, et al. (2005) (6,7-Dimethoxy-2,4-dihydroindeno[1, 2-c]pyrazol-3-yl)phenylamines: PDGF receptor tyrosine kinase inhibitors with broad anti-proliferative activity against tumor cells J Med Chem 48:8163-8173.
10. Hubl U and Stevenson DE (2001) In vitro enzymic synthesis of mammalian liver xenobiotic metabolites catalysed by ovine liver microsomal cytochrome P450. Enzyme Microb Technol 29:306-311.
11. Huskey SE, Magdalou J, Ouzzine M, Siest G, and Chiu SH (1994) N-glucuronidation reactions. III. Regioselectivity of N-glucuronidation of methylbiphenyl tetrazole, methylbiphenyl triazole and methylbiphenyl imidazole using human and rat recombinant UDP-glucuronosyltransferases stably expressed in V79 cells. Drug Metab Dispos 22:659-562.
12. Hutzler JM, Kolwankar D, Hummel MA, and Tracy TS (2002) Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 30:1194-1200.
13. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, and Dinney CPN (2000) Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6:2635-2643.
14. Kadlubar FF, Miller JA, and Miller EC (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37:805-814.
15. Kaji H and Kume T (2005) Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s). Drug Metab Dispos 33:60-67.
16. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
17. Kirkwood LC, Nation RL, and Somogyi AA (1998) Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. Clin Exp Pharmacol Physiol 25:266-270.
18. Kowalczyk I, Hawes EM, and McKay G (2000) Stability and enzymatic hydrolysis of quaternary ammonium-linked glucuronide metabolites of drugs with an aliphatic tertiary amine - implications for analysis. J Pharm Biomed Anal 22:803-811.
19. Kren V, Ulrichová J, Kosina P, Stevenson D, Sedmera P, Prikrylová V, Halada P, and Simánek V (2000) Chemoenzymatic preparation of silybine β-glucuronides and their biological evaluation. Drug Metab Dispos 28:1513-1517.
20. Li WW (2004) Tumor angiogenesis as a target for early intervention and cancer prevention Cancer Chemoprev 1:611-633.
21. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7: 255-269.
22. Mei J, Tuman RW, Ho C, Galemmo R, Sechler J, Devine A, Lu H, Garrabrant T, Ludovici D, Strobel E, et al. (2004) A novel PDGF receptor kinase inhibitor with dual anti-angiogenesis and tumor cell anti-proliferative activity, in AACR Annual Meeting, Orlando, FL, March 27-31, Abstract #3990. Proc Am Assoc Cancer Res 45:921.
23. Mohri K, Uesawa Y, and Uesugi T (2001) Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. J Chromatogr B 759:153-159.
24. Pahernik SA, Schmid J, Sauter T, Schildberg FW, and Koebe HG (1995) Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison. Xenobiotica 25:811-823.
25. Radominska-Pandya A, Little JM, and Czernik PJ (2001) Human UDP-glucuronosyltransferase 2B7. Curr Drug Metab 2:283-298.
26. Sakamoto K and Nakamura Y (1993) Urinary metabolites of pinacidil. II. Species difference in the metabolism of pinacidil. Xenobiotica 23:649-656.
27. Smith CP and Benet LZ (1986) Characterization of the isomeric esters of zomepirac glucuronide by proton NMR. Drug Metab Dispos 14:503-505.
28. Stearns RA, Miller RR, Doss GA, Chakravarty PK, Rosegay A, Gatto GJ, and Chiu SH (1992) The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey and human liver slices. Drug Metab Dispos 20:281-287.
29. Stone AN, MacKenzie PI, Galetin A, Houston BJ, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
30. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
31. Tuman RW, Mei J, Ho C, Galemmo R, Ludovici D, Baker J, Burns C, Devine A, Maharoof U, Sechler J, et al. (2004) Discovery of a novel, dual mechanism anti-angiogenic and antiproliferative agent with oral anti-tumor activity, in AACR Annual Meeting, Orlando, FL, March 27-31, Abstract #4558. Proc Am Assoc Cancer Res 45:921.
32. Vashishtha SC, Hawes EM, McCann DJ, Ghosheh O, and Hogg L (2002) Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles by liver microsomes: interspecies differences and structure-metabolism relationships. Drug Metab Dispos 30:1070-1076.
33. Watanabe Y, Nakajima M, and Yokoi T (2002) Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469.
34. Yan Z and Caldwell GW (2003) Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases. Eur J Drug Metab Pharmacokinet 28:223-232.
35. Yan Z, Caldwell GW, Jones WJ, and Masucci JA (2003) Cone voltage induced in-source dissociation of glucuronides in electrospray and implications in biological analyses. Rapid Commun Mass Spectrom 17:1433-1442.